These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 23535511

  • 21. Comparison of Therapeutic Effect of Apheresis Platelets and Buffy Coat-Derived Platelet Concentrates.
    Wang Z, Chen X, Zhang Y, Lu H, Ren L.
    Clin Lab; 2024 Aug 01; 70(8):. PubMed ID: 39193950
    [Abstract] [Full Text] [Related]

  • 22. High concentration plasma-reduced plateletapheresis concentrates.
    Perseghin P.
    Transfus Apher Sci; 2011 Jun 01; 44(3):273-6. PubMed ID: 21507725
    [Abstract] [Full Text] [Related]

  • 23. The ethics of wasting the donor's gift of buffy coat.
    Vamvakas EC.
    Vox Sang; 2011 Feb 01; 100(2):256-7; author reply 258-9. PubMed ID: 20825600
    [No Abstract] [Full Text] [Related]

  • 24. [Preparation of pooled granulocytes concentrates from whole blood buffy coats (PGC) as an alternative to apheresis].
    Mastronardi R, Cleophax S, Begué S, Hurtado-Nedelec M, Gross S, Bocquet T, Djoudi R.
    Transfus Clin Biol; 2019 Sep 01; 26(3):164-170. PubMed ID: 31400933
    [Abstract] [Full Text] [Related]

  • 25. Use of random versus apheresis platelet concentrates.
    Andreu G, Vasse J, Sandid I, Tardivel R, Semana G.
    Transfus Clin Biol; 2007 Dec 01; 14(6):514-21. PubMed ID: 18417401
    [Abstract] [Full Text] [Related]

  • 26. Prospective, paired crossover comparison of multiple, single-needle plateletpheresis procedures with the Amicus and Trima Accel cell separators.
    Fontana S, Mordasini L, Keller P, Taleghani BM.
    Transfusion; 2006 Nov 01; 46(11):2004-10. PubMed ID: 17076857
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Preparation and pathogen inactivation of double dose buffy coat platelet products using the INTERCEPT blood system.
    Abedi MR, Doverud AC.
    J Vis Exp; 2012 Dec 07; (70):e4414. PubMed ID: 23242463
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. In vivo recovery and survival of apheresis and whole blood-derived platelets: a paired comparison in healthy volunteers.
    Arnold DM, Heddle NM, Kulczycky M, Carruthers J, Sigouin C, Blajchman MA.
    Transfusion; 2006 Feb 07; 46(2):257-64. PubMed ID: 16441604
    [Abstract] [Full Text] [Related]

  • 31. Quality and safety of platelet apheresis concentrates produced with a new leukocyte reduction system.
    Riggert J, Humpe A, Simson G, Köhler M.
    Vox Sang; 1998 Feb 07; 74(3):182-8. PubMed ID: 9595646
    [Abstract] [Full Text] [Related]

  • 32. Collection, storage, inspection and quality control of platelet concentrates obtained by apheresis: The situation in Spain.
    Castrillo A, Jimenez-Marco T, Arroyo JL, Jurado ML, Larrea L, Maymo RM, Monge J, Muñoz C, Pajares Á, Yáñez M, Spanish Society of Blood Transfusion and Cellular Therapy (SETS) blood component production and processing workgroup.
    Transfus Apher Sci; 2017 Jun 07; 56(3):357-361. PubMed ID: 28319015
    [Abstract] [Full Text] [Related]

  • 33. In vitro and in vivo properties of various types of platelets.
    Rebulla P.
    Vox Sang; 1998 Jun 07; 74 Suppl 2():217-22. PubMed ID: 9704448
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Effects of high-yield thrombocytapheresis on the quality of platelet products.
    Julmy F, Ammann RA, Mansouri Taleghani B, Fontana S, Hirt A, Leibundgut K.
    Transfusion; 2008 Mar 07; 48(3):442-50. PubMed ID: 18067508
    [Abstract] [Full Text] [Related]

  • 36. In vitro and in vivo evaluation of apheresis platelets stored for 5 days in 65% platelet additive solution/35% plasma.
    Vassallo RR, Adamson JW, Gottschall JL, Snyder EL, Lee W, Houghton J, Elfath MD.
    Transfusion; 2010 Nov 07; 50(11):2376-85. PubMed ID: 20497516
    [Abstract] [Full Text] [Related]

  • 37. Overcoming the bottleneck of platelet lysate supply in large-scale clinical expansion of adipose-derived stem cells: A comparison of fresh versus three types of platelet lysates from outdated buffy coat-derived platelet concentrates.
    Glovinski PV, Herly M, Mathiasen AB, Svalgaard JD, Borup R, Talman MM, Elberg JJ, Kølle ST, Drzewiecki KT, Fischer-Nielsen A.
    Cytotherapy; 2017 Feb 07; 19(2):222-234. PubMed ID: 27887865
    [Abstract] [Full Text] [Related]

  • 38. In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days.
    Moog R, Fröhlich A, Mayaudon V, Lin L.
    J Clin Apher; 2004 Feb 07; 19(4):185-91. PubMed ID: 15597347
    [Abstract] [Full Text] [Related]

  • 39. Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components.
    Xiao W, Tormey CA, Capetillo A, Maitta RW.
    Vox Sang; 2013 Nov 07; 105(4):334-40. PubMed ID: 23802769
    [Abstract] [Full Text] [Related]

  • 40. A national survey of transfusion-related acute lung injury risk reduction policies for platelets and plasma in the United States.
    Kleinman S, Grossman B, Kopko P.
    Transfusion; 2010 Jun 07; 50(6):1312-21. PubMed ID: 20456690
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.